NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
More US tech stocks look cheap as the market rotates
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,430.60 | 80.60 | 0.86% |
| CAC 40 | 8,393.45 | 187.30 | -2.18% |
| DAX 40 | 24,673.10 | 611.16 | -2.42% |
| Dow JONES (US) | 48,876.81 | 101.11 | -0.21% |
| FTSE 100 | 10,754.36 | 156.19 | -1.43% |
| HKSE | 26,059.85 | 570.69 | -2.14% |
| NASDAQ | 22,630.06 | 38.15 | -0.17% |
| Nikkei 225 | 58,057.24 | 793.03 | -1.35% |
| NZX 50 Index | 13,656.65 | 66.32 | -0.48% |
| S&P 500 | 6,861.56 | 17.32 | -0.25% |
| S&P/ASX 200 | 9,200.90 | 81.20 | 0.89% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |